Wells Fargo & Company Cardiol Therapeutics Inc. Transaction History

Wells Fargo & Company

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$0.96 - $1.46 $1,896 - $2,883	-1,975 Reduced 98.75%	25 $0
Q3 2024 Nov 13, 2024	SELL	$1.83 - $2.48 $1,830 - $2,480	-1,000 Reduced 33.33%	2,000 $3,000
Q1 2024 May 10, 2024	BUY	$0.88 - $2.06 $2,640 - $6,180	3,000 New	3,000 $5,000
Q3 2023 Nov 13, 2023	BUY	$0.76 - $1.19 $114 - $178	150 New	150 $0

6.7M

37.6K

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $70M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.